ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval
FDA Okays Practice-Changing Treatment For Liver Cancer
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
